Industry News
Belgian ReVision Implant closes €4M oversubscribed seed for cortical vision prosthesis, with first-in-human trial cleared for Q3 2026
Belgian neurotech ReVision Implant closed an oversubscribed €4 million seed round in May 2026 to bring manufacturing of its Occular cortical vision prosthesis in-house ahead of a first-in-human trial cleared for Q3 2026 (October surgical-window cohort), with broader early-stage trials in blind volunteers expected in summer 2027. The round follows FDA Breakthrough Device Designation granted in March 2026.